Silybin Meglumine Mitigates CCl4-Induced Liver Fibrosis and Bile Acid Metabolism Alterations
Open Access
- 17 October 2024
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 14 (10) , 556
Abstract
Background: Altered patterns of bile acids (BAs) are frequently present in liver fibrosis, and BAs function as signaling molecules to initiate inflammatory responses. Silybin meglumine (SLB-M) is widely used in treating various liver diseases including liver fibrosis. However, research on its effects on bile acid (BA) metabolism is limited. This study investigated the therapeutic effects of SLB-M on liver fibrosis and BA metabolism in a CCl4-induced murine model. Methods: A murine liver fibrosis model was induced by CCl4. Fibrosis was evaluated using HE, picrosirius red, and Masson’s trichrome staining. Liver function was assessed by serum and hepatic biochemical markers. Bile acid (BA) metabolism was analyzed using LC-MS/MS. Bioinformatics analyses, including PPI network, GO, and KEGG pathway analyses, were employed to explore molecular mechanisms. Gene expression alterations in liver tissue were examined via qRT-PCR. Results: SLB-M treatment resulted in significant histological improvements in liver tissue, reducing collagen deposition and restoring liver architecture. Biochemically, SLB-M not only normalized serum liver enzyme levels (ALT, AST, TBA, and GGT) but also mitigated disruptions in both systemic and hepatic BA metabolism by increased unconjugated BAs like cholic acid and chenodeoxycholic acid but decreased conjugated BAs including taurocholic acid and taurodeoxycholic acid, compared to that in CCl4-induced murine model. Notably, SLB-M efficiently improved the imbalance of BA homeostasis in liver caused by CCl4 via activating Farnesoid X receptor. Conclusions: These findings underscore SLB-M decreased inflammatory response, reconstructed BA homeostasis possibly by regulating key pathways, and gene expressions in BA metabolism.Keywords
Funding Information
- National Natural Science Foundation of China (82304642, 82274200, 82074114, BK20221526, BK20210430, CPU2018GY33)
- Natural Science Foundation of Jiangsu Province (82304642, 82274200, 82074114, BK20221526, BK20210430, CPU2018GY33)
- “Double First—Class” University Project (82304642, 82274200, 82074114, BK20221526, BK20210430, CPU2018GY33)
This publication has 47 references indexed in Scilit:
- Targeting bile acid signaling for the treatment of liver diseases: From bench to bedBiomedicine & Pharmacotherapy, 2022
- Gamma‐glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community‐based cross‐sectional studyThe Kaohsiung Journal of Medical Sciences, 2021
- The role of the retinoid receptor, RAR/RXR heterodimer, in liver physiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2021
- Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesisEBioMedicine, 2021
- Protective effect of picroside I against hepatic fibrosis in mice via sphingolipid metabolism, bile acid biosynthesis, and PPAR signaling pathwayBiomedicine & Pharmacotherapy, 2020
- Organic Solute Transporter Alpha Deficiency: A Disorder With Cholestasis, Liver Fibrosis, and Congenital DiarrheaHepatology, 2020
- FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver TumorigenesisDevelopmental Cell, 2019
- Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseasesPhytotherapy Research, 2018
- Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer – A comprehensive reviewEuropean Journal of Medicinal Chemistry, 2016
- Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cellsJournal of Hepatology, 2009